Clinical trials: IDIOPATHIC PARKINSON'S DISEASE
Parkinson's Disease, Idiopathic
A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD
The purpose of this study is to measure safety and efficacy of buntanetap/posiphen capsules compared with placebo capsules in participants with early PD. Study details include: The study duration will be up to 7-8 months.
- Trial name
- NCT05357989
- Testing
- buntanetap/posiphen
- Where
- 69 sites in United States, Germany and 4 more
- Volunteers
- 523 people
- Sponsor
- Annovis Bio Inc.
Parkinson Disease, Idiopathic Parkinson Disease
An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)
The primary purpose of this extension study is to assess the long-term safety and tolerability of preladenant in participants from parent studies NCT01155466 [P04938] and NCT01227265 [P07037] with moderate to severe Parkinson's…
- Trial name
- NCT01215227
- Testing
- Preladenant, Rasagiline
- Volunteers
- 839 people
- Sponsor
- Merck Sharp & Dohme LLC
Parkinson's Disease
A Study of Three Doses of TCH346 in Patients With Early Parkinson's Disease to Evaluate Safety and Efficacy
This study will investigate the effect of TCH346 compared to placebo in delaying the need for symptomatic treatment with dopaminergic agents
- Trial name
- NCT00407212
- Testing
- TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)
- Where
- 45 sites in United States, Brazil and 7 more
- Volunteers
- 301 people
- Sponsor
- Novartis
Parkinson's Disease
Efficacy and Safety of BIA 9-1067 in Idiopathic Parkinson's Disease Patients.
Parkinson's disease (PD) is a neurodegenerative disorder of unknown aetiology with an estimated incidence of 4.5-16/100,000 persons/year.
- Trial name
- BIPARKII (NCT01227655)
- Testing
- BIA 9-1067, Levodopa, Carbidopa
- Where
- Portugal
- Volunteers
- 427 people
- Sponsor
- Bial - Portela C S.A.
Parkinson's Disease
ExAblate Transcranial MRgFUS of the Subthalamic Nucleus for Treatment of Parkinson's Disease
This is primarily a safety protocol to evaluate the safety of subthalamotomy using Transcranial ExAblate for treatment of Parkinson's Disease (PD) motor features.
- Trial name
- NCT02246374
- Testing
- ExAblate Transcranial System
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- InSightec
Idiopathic Parkinson Disease
Clinical Outcome Assessment of Parkinson's Disease Patients Treated With XADAGO (Safinamide)
This is a Phase IV, prospective, observational, post-marketing study designed to obtain additional data on the effect of XADAGO on motor and non-motor symptoms in Parkinson's Disease patients newly prescribed XADAGO.
- Trial name
- PRO-Go (NCT03944785)
- Testing
- XADAGO (safinamide)
- Where
- 30 sites in United States
- Volunteers
- 164 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Parkinson's Disease
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: Group 1 Patients using Azilect and no other therapy.
- Trial name
- NCT00399477
- Testing
- rasagiline mesylate, Rasagiline mesylate plus Mirapex, Rasagiline mesylate with Levodopa
- Volunteers
- 200 people
- Sponsor
- Teva Neuroscience, Inc.
Parkinson's Disease
Study of NP002 in Subjects With Idiopathic Parkinson's Disease to Treat Dyskinesias Due to Levodopa Therapy
The study is designed to answer the question: will nicotine at doses that do not cause serious side effects, show feasibility in treatment of levodopa-induced dyskinesia in patients with Parkinson's disease?
- Trial name
- NCT00957918
- Testing
- nicotine
- Where
- 12 sites in United States
- Volunteers
- 65 people
- Sponsor
- Neuraltus Pharmaceuticals, Inc.
Idiopathic Parkinson's Disease
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.
- Trial name
- NCT00985517
- Testing
- CERE-120: Adeno-Associated Virus Delivery of Neurturin
- Where
- 11 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sangamo Therapeutics
Parkinson's Disease
Efficacy and Safety of Safinamide (50 and 100mg/Day) Versus Placebo, in Patients With Mid-late Stage Parkinson's Disease
The purpose of this study is to evaluate the efficacy and safety of two doses of safinamide (50 and 100 mg/day, p.o.), compared to placebo, as add-on therapy in patients with idiopathic Parkinson's disease with motor fluctuations…
- Trial name
- NCT01187966
- Testing
- Safinamide
- Volunteers
- 669 people
- Sponsor
- Newron Pharmaceuticals SPA
Idiopathic Parkinson's Disease
Infusion of Apomorphine: Long-term Safety Study
This is a Phase 3, multicenter, open-label, safety and tolerability study of continuous apomorphine infusion in subjects with advanced Parkinson's Disease (PD) whose motor fluctuations remain unsatisfactory with levodopa (or…
- Trial name
- INFUS-ON (NCT02339064)
- Testing
- apomorphine infusion
- Where
- 18 sites in United States
- Volunteers
- 99 people
- Sponsor
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Idiopathic Parkinson's Disease
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
Parkinson's disease is a major neurodegenerative disorder in which there is a progressive loss of nigrostriatal dopaminergic neurons.
- Trial name
- MOTION (NCT01028586)
- Testing
- Safinamide, MAO-B inhibitor
- Where
- Switzerland
- Volunteers
- 507 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinson's Disease (Disorder)
A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations
To evaluate the safety and efficacy of IPX203 (carbidopa and levodopa) extended-release capsules (IPX203 ER CD-LD) in comparison to immediate release (IR) CD-LD in the treatment of CD-LD-experienced participants with Parkinson's…
- Trial name
- NCT03670953
- Testing
- IR CD-LD, IPX203 ER CD-LD
- Where
- 108 sites in United States, Czechia and 6 more
- Volunteers
- 630 people
- Sponsor
- Impax Laboratories, LLC
Idiopathic Parkinson's Disease
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
The purpose of this study is to determine the safety, efficacy and pharmacokinetics following administration of CVT-301 in treatment of "off" episodes in Parkinson's Disease patients.
- Trial name
- NCT01617135
- Testing
- CVT-301, Sinemet (carbidopa/levodopa)
- Where
- 7 sites in Israel, Serbia and 1 more
- Volunteers
- 25 people
- Sponsor
- Acorda Therapeutics
Early-Stage Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease.
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease.
- Trial name
- SP512OL (NCT00594165)
- Testing
- Rotigotine
- Where
- 42 sites in United States, Canada
- Volunteers
- 217 people
- Sponsor
- UCB Pharma
Early Stage Parkinson's Disease
An Open-Label Extension Trial to Assess the Safety of Long-Term Treatment of Rotigotine in Early-Stage Parkinson's Disease
The objective of this open-label extension is to assess the safety and tolerability of long-term treatment of the rotigotine patch in subjects with early-stage idiopathic Parkinson's disease
- Trial name
- NCT00599196
- Testing
- Rotigotine
- Where
- 63 sites in Australia, Austria and 18 more
- Volunteers
- 381 people
- Sponsor
- UCB Pharma
Parkinson Disease
The Effect of Sifrol® on Tremor and Depression in Patients With Idiopathic Parkinson's Disease
Documentation of the effect of SIFROL® on tremor and depression as well as its tolerability in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions
- Trial name
- NCT02231294
- Testing
- Sifrol®
- Volunteers
- 1,464 people
- Sponsor
- Boehringer Ingelheim
Idiopathic Parkinson Disease
Parkinsonian Brain Repair Using Human Stem Cells
Implantation of Celavie human stem cells (OK99) is intended to address the underlying pathology of the disease by replacing damaged/destroyed cells of the brain, and/or stimulating the patient's brain to repair itself.
- Trial name
- HSCfPD (NCT02780895)
- Testing
- Human Stem Cells
- Where
- Mexico
- Volunteers
- 8 people
- Sponsor
- Celavie Bioscences, LLC
Parkinson Disease
Evaluate the Effectiveness and Safety of Variable Frequency Stimulation Compared With Constant Frequency Stimulation for Patients With Idiopathic Parkinson's Disease
In the VFS paradigm the stimulation frequency was set to alternate between high and low frequencies, where the frequency of stimulation or frequency combinations can be changed instantaneously according to damage of the moment…
- Trial name
- NCT03053726
- Testing
- Variable Frequency Stimulation
- Where
- 9 sites in China
- Volunteers
- 106 people
- Sponsor
- Beijing Pins Medical Co., Ltd
Depressive Symptoms, Parkinson's Disease
Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn
The primary endpoint for this study is the clinical response after 12 weeks of treatment, defined as a change in total score from baseline depressive symptoms as measured by the Beck Depression Inventory-Amended (BDI-IA) total…
- Trial name
- ACCORDO (NCT01055379)
- Testing
- Rasagiline
- Where
- 12 sites in Italy
- Volunteers
- 121 people
- Sponsor
- Lundbeck Italia S.p.A.